Pancreatic neuroendocrine tumors are an uncommon but stubborn group of malignancies. Unlike the more familiar pancreatic adenocarcinomas, they often express high levels of somatostatin receptors on their surface, a molecular feature that has made them eligible for peptide receptor radionuclide therapy. In this approach, a hormone-like peptide called DOTATATE binds to those receptors and delivers a radioactive payload, lutetium-177, directly into tumor cells. The beta radiation released by lutetium-177 travels only a few millimeters in tissue, damaging DNA and triggering cell death in tumor cells while largely sparing surrounding healthy tissue. Clinical trials have shown meaningful benefit, but responses are rarely complete, and resistance eventually develops in many patients.

Sunitinib, meanwhile, is a multitargeted oral kinase inhibitor that blocks several receptors involved in tumor angiogenesis, including vascular endothelial growth factor receptors and platelet-derived growth factor receptors. By starving tumors of their blood supply and directly inhibiting survival signaling within tumor cells, sunitinib has extended progression-free survival in patients with advanced pancreatic neuroendocrine tumors. Clinicians have observed that combining sunitinib with 177Lu-DOTATATE appears to produce deeper and more lasting responses, but the biological basis of this synergy remained poorly defined.

The new research set out to test a specific hypothesis: that the combination does more than simply add two cytotoxic effects. Immunogenic cell death is a specialized form of cell demise in which dying tumor cells release or expose a characteristic set of signals, often called damage-associated molecular patterns. These include calreticulin translocated to the cell surface, secretion of ATP, release of high-mobility group box 1 protein, and presentation of tumor antigens on major histocompatibility complex molecules. Together, these signals attract and activate dendritic cells, which then carry tumor antigens to lymph nodes and prime cytotoxic T lymphocytes capable of hunting down residual cancer cells throughout the body.

Using preclinical models of pancreatic neuroendocrine tumors, the investigators showed that each therapy alone induced only limited immunogenic signaling. Sunitinib treatment produced vascular changes and some direct tumor cell stress, while 177Lu-DOTATATE delivered DNA-damaging radiation that killed a fraction of receptor-expressing cells. Neither monotherapy reliably provoked the full repertoire of immunogenic death markers. When the two were combined, however, the picture changed dramatically. Tumor cells exposed to both agents displayed significantly increased surface calreticulin, elevated ATP secretion, and heightened release of high-mobility group box 1 protein into the tumor microenvironment.

The mechanistic studies went further. The researchers found that sunitinib pretreatment increased the expression of entosis-related and autophagy pathways in tumor cells, processes that are known to be required for the calreticulin exposure that defines immunogenic cell death. At the same time, radiation from lutetium-177 inflicted the DNA damage and endoplasmic reticulum stress that serve as the danger signals alerting the immune system. In effect, the kinase inhibitor appeared to prepare tumor cells for a form of death that the radiopharmaceutical then converted into an immunological alarm, transforming what would otherwise be a quiet, non-inflammatory demise into a stimulus capable of recruiting dendritic cells and activating T cells.

The immune consequences were visible within the tumors themselves. Combination-treated tumors showed increased infiltration by CD8-positive cytotoxic T lymphocytes, higher ratios of effector T cells to immunosuppressive regulatory T cells, and evidence of dendritic cell activation. Interferon-gamma signatures were upregulated, indicating that T cells within the tumor microenvironment had been functionally engaged rather than merely present. The researchers also documented reductions in myeloid-derived suppressor cells and markers of tumor-associated immunosuppression, suggesting that the combination remodels the tumor microenvironment in a direction that favors immune attack.

Perhaps the most striking evidence came from experiments in which the researchers depleted specific immune cell populations or blocked key signaling pathways. When CD8-positive T cells were removed, the survival advantage and tumor control conferred by the combination largely disappeared, demonstrating that the adaptive immune response was not an incidental byproduct but a required component of the therapeutic synergy. Similarly, blocking the recognition of damage-associated molecular patterns abrogated the dendritic cell activation and downstream T cell priming. These findings establish the combination as a bona fide inducer of a vaccination-like effect arising from within the tumor itself.

The implications for clinical practice are considerable. Immunogenic cell death has become one of the central concepts in the rational design of combinations with immune checkpoint inhibitors, since checkpoint blockade works best when antitumor T cells have already been primed. The new findings provide a mechanistic rationale for testing 177Lu-DOTATATE and sunitinib together with agents such as PD-1 or PD-L1 inhibitors in pancreatic neuroendocrine tumors, a disease in which immunotherapy alone has so far shown limited activity. Ongoing and planned clinical trials may now incorporate biomarkers of immunogenic cell death, such as serum high-mobility group box 1 levels or tumor calreticulin staining, as pharmacodynamic readouts of whether the combination is successfully igniting antitumor immunity in individual patients.

The study also carries broader lessons for nuclear medicine. Radiopharmaceuticals have often been viewed as precision cytotoxic tools whose benefits are confined to their radioactive range. Work of this kind reinforces an emerging view that targeted radionuclide therapy can function as an in situ tumor vaccine, and that pairing it with agents that modulate tumor cell death pathways, vascular biology, or immune checkpoints can convert localized radiation into systemic immunological control. For patients with pancreatic neuroendocrine tumors, whose treatment options narrow sharply after somatostatin analogs, everolimus, sunitinib, and 177Lu-DOTATATE have been exhausted, the prospect of a combination that teaches the immune system to finish what the drugs begin offers a genuinely new therapeutic direction grounded in a mechanism that can now be measured, monitored, and deliberately enhanced.

Subject of Research: Mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy via immunogenic cell death in pancreatic neuroendocrine tumors

Article Title: Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors

Article References: Essler, M., Veit, N., Müller, A., Marinova, M., & Kreppel, B. (2026). Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors. Cell Death Discovery, 12(1), Article 379. https://doi.org/10.1038/s41420-026-03344-z

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03344-z

Keywords: immunogenic cell death, sunitinib, 177Lu-DOTATATE, peptide receptor radionuclide therapy, pancreatic neuroendocrine tumors, calreticulin, damage-associated molecular patterns, dendritic cells, CD8 T cells, tumor microenvironment, radiopharmaceuticals, immunotherapy synergy